Knight Therapeutics (Knight Therapeutics Stock Quote, Chart, News, Analysts, Financials TSXV:GUD) is continuing to build momentum, according to Stifel Nicolaus Canada analyst Justin Keywood, who maintained his “Buy” rating and $7.45 target price following the company’s first-quarter earnings release on May 8. Keywood said Knight is steadily assembling a diversified global portfolio of pharmaceutical assets […]
In a May 5 investor note, Leede Financial analyst Douglas Loe reiterated his Speculative Buy rating and $3.00 target for Perimeter Medical Imaging (Perimeter Medical Imaging Stock Quote, Chart, News, Analysts, Financials TSXV:PINK), citing new clinical data for its next-generation, AI-enabled B-Series OCT platform. Based in Ontario and Texas, Perimeter has already received FDA approval […]
Share
Tweet
Share
